3-(1H-imidazol-5-ylmethylidene)-5-methoxy-1H-indol-2-one | 666837-93-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(1H-imidazol-5-ylmethylidene)-5-methoxy-1H-indol-2-one
• CAS: 666837-93-0
• 化学式: C₁₃H₁₁N₃O₂
• 分子量: 241.24
• InChiKey: QNUKRWAIZMBVCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER
  申请人：Virginia Commonwealth University

  公开号：EP1496908A1

  公开（公告）日：2005-01-19
• Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
  申请人：Dent Paul

  公开号：US20050176725A1

  公开（公告）日：2005-08-11

  The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Abl + leukemia resistant to compound of formula I.
• METHOD TO GENERATE INDUCED OLIGODENDROCYTE-LINEAGE CELLS AND TREATMENT USING SUCH CELLS
  申请人：ACADEMIA SINICA

  公开号：US20210246422A1

  公开（公告）日：2021-08-12

  The present invention generally relates to a method for generating induced oligodendrocyte-lineage cells (induced OLGs) and treatment using such cells. The induced OLGs are useful in cell therapy, in particular for demyelinating diseases.
• US7888341B2
  申请人：——

  公开号：US7888341B2

  公开（公告）日：2011-02-15
• [EN] COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER<br/>[FR] COMBINAISON DE GLIVEC (STI571) AVEC UN INHIBITEUR DE KINASE DEPENDANTE DES CYCLINES, NOTAMMENT DU FLAVOPIRIDOL, DESTINEE AU TRAITEMENT DU CANCER
  申请人：UNIV VIRGINIA COMMONWEALTH

  公开号：WO2003084543A1

  公开（公告）日：2003-10-16

  The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Abl+ leukemia resistant to compound of formula (I).